Nicosive Nicotine Transdermal Patch. A structured, step-down approach to smoking cessation with 24-hour controlled nicotine delivery.
Quick Links
Healthcare Professionals
72 Hours Action | 7×1 Patch per Box | Hetero Healthcare
Disclaimer
This document is intended for healthcare professionals only. The information provided is based on published clinical data and real-world evidence. Please consult prescribing information before recommending therapy.
India faces one of the world's most significant tobacco crises. With approximately 243.48 million tobacco users aged 15 and older as of 2024, the burden of tobacco-related morbidity and mortality remains a pressing public health challenge.
Despite a decline in prevalence, absolute numbers remain high owing to India's vast and growing population.
Nicosive (Nicotine Transdermal Patch) by Hetero Healthcare is a clinically proven Nicotine Replacement Therapy (NRT) formulated to deliver controlled transdermal nicotine at three stepped doses - 7 mg, 14 mg, and 21 mg - over 72 hours per patch.
Nicosive is designed to ease nicotine dependence safely, gradually, and effectively, without smoke, tar, or harmful combustion by-products.
Understanding the barriers that prevent successful quit attempts is essential for effective intervention.
Irritability, anxiety, poor concentration, insomnia - peaking in weeks 1-2
Triggered by stress, social cues, alcohol, or habitual settings
Tobacco use deeply embedded in social and rural practices
Limited counselling infrastructure in Tier 2/3 cities and rural India
Lower awareness and affordability of cessation aids
Nicotine dependence is driven by:
1
Skin reActivation of nicotinic acetylcholine receptors (nAChRs) dness and itching
2
Dopamine release in mesolimbic pathways
3
Neuroadaptation with receptor upregulation
4
Withdrawal symptoms upon abrupt cessation
1
Irritability
2
Anxiety
3
Restlessness
4
Poor concentration
5
Sleep disturbance
6
Increased appetite
7
Intense cravings
The intensity of withdrawal is a key determinant of early relapse.
1
Reduce withdrawal severity
2
Prevent rapid dopamine fluctuation
3
Break the spike-and-crash reinforcement cycle
4
Allow neurobiological stabilization during tapering
Nicotine exerts its primary addictive effect by binding to nicotinic acetylcholine receptors (nAChRs) in the mesolimbic dopamine system. This triggers dopamine release in the nucleus accumbens, producing reinforcement and reward. Over time, receptor upregulation occurs, making the brain dependent on exogenous nicotine to maintain baseline dopaminergic tone. Abrupt cessation creates a withdrawal syndrome characterised by intense craving, dysphoria, anxiety, and cognitive impairment.
Nicosive employs a Transdermal Drug Delivery System (TDDS), a controlled-release mechanism that delivers nicotine directly through the skin into the systemic bloodstream - bypassing gastrointestinal metabolism and providing stable plasma concentrations over 72 hours.
| Parameter | Cigarette Nicotine | Nicosive Patch Nicotine |
|---|---|---|
| Delivery route | Pulmonary inhalation | Transdermal absorption |
| Onset profile | Rapid spike (7-10 seconds) | Gradual, sustained release |
| Plasma nicotine | Sharp peaks & deep troughs | Steady therapeutic levels |
| Associated chemicals | 4,000+ chemicals incl. CO, tar, carcinogens | 72 hours per patch |
| Duration of action | Minutes per cigarette | 72 hours per patch |
| Craving management | Relief only during smoking | Continuous background suppression |
Nicosive's three-strength system mirrors evidence-based step-down NRT protocols recommended by the WHO and clinical cessation guidelines
| Dependence Level | CPD | TTFC | FTND Score | Clinical Profile | NRT Recommendation |
|---|---|---|---|---|---|
| High | > 20 | ≤ 30 min | 7–10 | Strong cravings, withdrawal, compulsive smoking | 21 mg |
| Moderate | 10-20 | 30-60 min | 4-6 | Regular smoker, moderate cravings | 14 mg |
| Low | <10 | > 60 min | 0-3 | Occasional / behavioral smoking | 7 mg |
This graduated approach prevents abrupt nicotine withdrawal, manages cravings progressively, and significantly reduces relapse risk compared to unaided cessation.
Nicotine transdermal patches, including Nicosive, have a well-established and extensively documented safety profile
| Side Effect | Frequency | Nature | Management |
|---|---|---|---|
| Local skin reaction (redness, itching) | Common (10-20%) | Mild, localised | Rotate application site daily |
| Sleep disturbances / vivid dreams | Common (5-15%) | Mild, transient | Remove patch before sleep if nocturnal dreams occur |
| Mild headache | Common (5-10%) | Mild, transient | Adequate hydration; resolves spontaneously |
| Nausea | Uncommon (2-5%) | Mild | Apply to hairless upper arm/back; avoid meals timing |
| Systemic nicotine effects | Rare | Only with concomitant smoking | Reinforce no concurrent tobacco use |
Nicotine replacement therapy is the most extensively studied pharmacological intervention for tobacco cessation
Evidence Base for Nicotine Replacement Therapy
Nicotine replacement therapy is the most extensively studied pharmacological intervention for tobacco cessation. The following summarises key evidence supporting NRT, including transdermal patch formulations:
Multiple Cochrane systematic reviews and meta-analyses demonstrate that NRT consistently doubles the probability of sustained abstinence compared to placebo or unassisted quitting.
Key Finding: NRT patches more than double 6-month quit rates vs. unassisted attempts.
Transdermal NRT: 15-25% abstinence at 6 months Control arms: 6-10% abstinence
Reference: Stead LF et al. (2012), Cochrane Database of Systematic Reviews
The 72-hour patch application frequency of Nicosive - requiring patch change only every 3 days - addresses one of the most significant barriers to NRT compliance: daily application burden. Studies comparing 16-hour to 24-hour NRT patches show adherence is significantly influenced by application frequency. Extended-duration patches are associated with improved treatment completion, particularly in working-age adults and patients in rural or resource-limited settings.
A randomised controlled trial by Stapleton JA et al. demonstrated that structured step-down NRT protocols produce significantly higher sustained abstinence at 12 months compared to abrupt cessation, with relapse rates dropping by 30-40% in the step-down arm. The Nicosive 21 mg → 14 mg → 7 mg protocol directly mirrors this evidence-based approach.
A meta-analysis of over 20,000 patients confirmed that even a brief (3-minute) physician intervention advising cessation increases quit rates significantly. When NRT is combined with brief physician counselling, success rates at 6 months are 2-3 times higher than NRT alone.
The following case studies are illustrative clinical vignettes representative of patient profiles commonly encountered in cessation practice in India. They are based on documented patient archetypes and NRT clinical literature and are intended for educational purposes for healthcare professionals.
| Patient: | Mr. Rajesh K., 48 years, Male |
| Occupation: | Self-employed businessman, Mumbai |
| Smoking history: | 22 cigarettes/day for 24 years; Fagerström Score: 8/10 (high dependence) |
| Co-morbidities: | Stage 1 hypertension (on Amlodipine 5 mg), no cardiac events |
| Previous quit attempts: | 3 prior unaided attempts; longest abstinence: 11 days |
| Trigger for current attempt: | Persistent morning cough and breathlessness on stairs; spouse's pressure |
Patient presented to his cardiologist reporting worsening exertional dyspnoea. Spirometry indicated early obstructive pattern. Given his high nicotine dependence score and cardiovascular comorbidity, the physician determined that continued smoking posed a substantially greater cardiovascular risk than controlled NRT delivery.
Prescription
Nicosive 21 mg transdermal patch, 1 patch every 72 hours for 6 weeks, applied to right upper arm on clean dry skin, rotating site each application.
Counselling Provided
B.R.E.A.K. method (Breathe, Replace, Exercise, Avoid Triggers, Keep Busy); advised against concurrent smoking; sleep monitoring requested.
Week 2
Tobacco-free; mild skin erythema at application site (Grade 1)
Moderate cravings, mild irritability - Full adherence, site rotation advised
Week 4
Sustained abstinence; erythema resolved with site rotation
Cravings significantly reduced - Full adherence
Week 6
Abstinent; BP improved to 128/82 mmHg
Cravings significantly reduced - Full adherence
Week 10
Abstinent; spirometry improvement noted
Negligible cravings - Full adherence, transitioned to 7 mg
Week 12
Tobacco-free; energy levels improved
No significant cravings - Complete course finished
3 Months post-treatment
Sustained abstinence confirmed; BP 122/78 mmHg
No withdrawal symptoms
Clinical Outcome
12-week sustained tobacco abstinence achieved. Systolic BP reduction of 14 mmHg. Improvement in exertional tolerance. No significant cardiovascular adverse events during NRT therapy. Patient reported improved sleep quality and appetite from Week 3.
Key Learning
In cardiovascular patients, the risk-benefit calculation strongly favours NRT over continued smoking. Nicosive's 72-hour patch format reduced daily adherence friction, critical in a high-stress self-employed individual.
| Patient: | Ms. Priya S., 29 years, Female |
| Occupation: | IT professional, Bengaluru |
| Smoking history: | 9 cigarettes/day for 6 years; Fagerström Score: 4/10 (moderate dependence) |
| Co-morbidities: | Nil significant; planning pregnancy in 6–12 months |
| Previous quit attempts: | 2 attempts; relapsed within 3 weeks (occupational stress triggers) |
| Trigger for current attempt: | Pre-conception planning; advised by gynaecologist to quit |
Gynaecologist counselled patient on smoking-associated risks: subfertility, early pregnancy loss, low birth weight, and neonatal complications. Given moderate dependence and predominantly stress-linked smoking patterns, a 14 mg → 7 mg step-down regimen was prescribed with integrated behavioural support.
Prescription
Nicosive 14 mg transdermal patch, 1 patch every 72 hours for 6 weeks; then step-down to Nicosive 7 mg for 4 weeks.
Week 1–2
Tobacco-free from Day 3 of patch use
Mild sleep disturbance (resolved by Week 2); mild
Week 4
Sustained abstinence
No cravings during work; social cravings managed by avoiding smoking zones
Week 6
Abstinent; stepped down to 7 mg
No rebound cravings post step-down; skin reaction nil
Week 10
Tobacco-free; course completed
Reports improved skin clarity, better sleep, no breathlessness
6-Month follow-up
Sustained abstinence; conceived naturally
No tobacco use reported; pregnancy confirmed at 7 months
Clinical Outcome
Full cessation achieved within 4 days of initiating Nicosive therapy. 10-week programme completed with zero tobacco use. Successful natural conception at 7 months. Patient attributed adherence to the 72-hour patch convenience fitting her demanding work schedule.
Key Learning
In young women in the reproductive age group, the clinical urgency of cessation is high. Moderate-dose NRT initiation (14 mg) with behavioural support produces excellent outcomes. The 72-hour patch format is particularly compatible with professional lifestyles.
| Patient: | Mr. Shankar R., 55 years, Male |
| Occupation: | Agricultural worker, Nashik district, Maharashtra |
| Tobacco history: | Mixed use - 8 bidis/day + khaini (smokeless tobacco); 30+ years; Fagerström: 5/10 |
| Co-morbidities: | Type 2 diabetes (on Metformin); oral submucous fibrosis (OSMF) |
| Previous quit attempts: | Never attempted; not aware of cessation support options |
| Trigger for current attempt: | OSMF diagnosis; referred by dental surgeon to physician |
Dental surgeon detected OSMF at a routine camp. Patient was referred to a primary care physician who assessed nicotine dependence and co-morbidities. Given his rural context, limited healthcare access, and mixed tobacco use pattern, the physician opted for the 7 mg patch as a conservative entry point, supplemented by telephone-based counselling available through the national Quitline (1800-11-2356).
Prescription
Nicosive 7 mg transdermal patch, 1 patch every 72 hours for 8 weeks. Applied to upper back skin (clean, dry area). Family member educated on application technique.
Week 1
Bidis stopped; smokeless tobacco reduced by 70%
Mild nausea (resolved); daughter assisted with patch application
Week 3
All tobacco products stopped
Blood glucose monitoring continued; no HbA1c deterioration
Week 6
Tobacco-free; OSMF symptoms stable
Attending 2-weekly dental review; improved mouth opening noted
Week 8
Course completed; tobacco-free
No relapse; family support cited as critical factor
3-Month follow-up
Sustained abstinence
OSMF stable; blood glucose improved; HbA1c reduced by 0.6%
Clinical Outcome
Complete cessation of all tobacco products by Week 3. Improved glycaemic control (HbA1c −0.6% at 3 months - consistent with evidence that smoking cessation improves insulin sensitivity). OSMF lesions stable with improvement in interincisal distance. Family-assisted application addressed literacy and application barriers effectively.
Key Learning
NRT is viable and effective even in polypharmacy, multi-tobacco-type rural patients. The 7 mg patch as a conservative starting point with family support integration addresses real-world adherence barriers in resource-limited settings.
| Patient: | Mr. Gopalakrishnan V., 62 years, Male |
| Occupation: | Retired government officer, Chennai |
| Smoking history: | 30 cigarettes/day for 35 years; Fagerström: 9/10 (very high dependence) |
| Co-morbidities: | COPD GOLD Stage II; hypertension; no active cardiac disease |
| Previous quit attempts: | 5 prior attempts; longest abstinence 3 weeks (Willpower only) |
| Trigger for current attempt: | Acute exacerbation of COPD requiring hospitalisation |
Following discharge from a COPD exacerbation, the treating pulmonologist initiated smoking cessation counselling as part of pulmonary rehabilitation. Given very high nicotine dependence and the critical need for cessation in COPD management, Nicosive 21 mg was prescribed with outpatient pulmonary rehab follow-up.
Prescription
Nicosive 21 mg patch, 72-hour application, for 8 weeks → Nicosive 14 mg for 4 weeks → Nicosive 7 mg for 4 weeks. Total planned programme: 16 weeks.
Baseline (discharge)
Abstinent (post-hospitalisation)
FEV1: 52% predicted, CAT Score: 22 (high impact)
Week 4 (21 mg)
Abstinent; 1 slip at week 3 (returned immediately)
FEV1: 54% predicted, CAT Score: 18
Week 8 (step to 14 mg)
Fully abstinent
FEV1: 56% predicted, CAT Score: 14
Week 12 (step to 7 mg)
Fully abstinent
FEV1: 58% predicted, CAT Score: 11
Week 16 (end of therapy)
Fully abstinent
FEV1: 61% predicted, CAT Score: 9 (low impact)
6-Month follow-up
Sustained abstinence; 0 exacerbations
FEV1: 63% predicted, CAT Score: 7
CAT = COPD Assessment Test (score ≥10 = medium-high symptom impact; < 10 = low impact). FEV1 improvement reflects both cessation benefit and pulmonary rehabilitation.
Clinical Outcome
Sustained 6-month abstinence achieved following one minor slip at Week 3. FEV1 improved by 11 percentage points at 6 months. CAT score reduced from 22 to 7 - a clinically significant symptom burden reduction. Zero COPD exacerbations in the 6-month post-treatment period. Patient reported markedly improved exercise tolerance and sleep quality.
Key Learning
For COPD patients, smoking cessation is the single most effective disease-modifying intervention. Structured NRT using Nicosive's step-down protocol, combined with pulmonary rehabilitation, produced measurable spirometric and symptomatic improvement within 16 weeks.
Use the patch strength prescribed by your doctor
Continue for the full recommended duration (8-12 weeks)
Combine with counselling for maximum efficacy
Rotate application sites to prevent skin reactions
Seek physician guidance before stopping early
Do not smoke or use tobacco while wearing the patch
Do not cut or alter the patch in any way
Do not apply to broken, irritated, or inflamed skin
Do not reuse a patch once removed
Do not apply to oily skin without cleansing first
Product Name
Nicosive (Nicotine Transdermal Patch)
Manufacturer
Hetero Healthcare
Available Strengths
Nicosive 7 mg / 14 mg / 21 mg - each delivers dose per 24 hours
Patch Duration
72 hours (3 days) per patch
Pack Size
7×1 patch per box (1 week's supply)
Indication
Nicotine Replacement Therapy for tobacco use disorder / smoking cessation
Starting Dose
21 mg: >20 cigs/day; 14 mg: 10–20 cigs/day; 7 mg: < 10 cigs/day or step-down
Recommended Duration
12 weeks minimum; up to 16 weeks for high-dependence patients
Step-Down Protocol
21 mg (6-8 wks) → 14 mg (4 wks) → 7 mg (4 wks)
Contraindications
Hypersensitivity to nicotine or patch components; recent (2 wk) MI/stroke - use with caution
Drug Interactions
Cessation may alter clearance of theophylline, clozapine, olanzapine (monitor levels)
NRT + Counselling
Strongly recommended - doubles sustained quit rates vs. NRT alone
References
1. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
2. Singh R, Nahid S, Mishra R, Ali A, Yadav PK. Tobacco cessation in India: Current trends, challenges, successes - A narrative review. J Global Oral Health. 2025;8:57-60.
3. Singh A, Kishore K. Smoking cessation in India: A narrative review. Lung India. 2025 Nov 1;42(6):532–536.
4. National Family Health Survey (NFHS) Phase 1, 2019–20. Ministry of Health and Family Welfare, Government of India.
5. Akshi Chawla (2022). The worrying patterns of tobacco consumption in India. Centre for Economic Data and Analysis (CEDA), Ashoka University.
6. Global Adult Tobacco Survey (GATS) India. Ministry of Health and Family Welfare & WHO. 2016–17.
7. WHO Report on the Global Tobacco Epidemic. World Health Organization, Geneva.
8. Tob. Prev. Cessation 2021;7(March):19 - Prevalence of tobacco use among men and women across states of India.
9. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390–395.
10. Medline Plus - Nicotine Transdermal Patch. US National Library of Medicine. medlineplus.gov.
Nicosive Nicotine Transdermal Patch. A structured, step-down approach to smoking cessation with 24-hour controlled nicotine delivery.
Quick Links
Nicosive Nicotine Transdermal Patch. A structured, step-down approach to smoking cessation with 24-hour controlled nicotine delivery.